Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 943-953

  Ackland, S ^a   Anton, A ^a,a   Breitbach, G P ^a,a   Colajori, E ^a   Tursi, J M ^a   Delfino, C ^a   Efremidis, A ^a   Ezzat, A ^a   Fittipaldo, A ^a   Kolaric, K ^a   Lopez, M ^a   Viaro, D ^a   Abdi, E ^a   Kotasek, D ^a   Beadle, G ^a   Friedlander, M ^a   Aranda, E ^a   Murillo, E ^a   Nogueira, M ^a   Balli, M ^a   De Lena, M ^a   Lopez II, M ^a   Luporini, G ^a   Micheletti, E ^a   Morrica, B ^a   Tordiglione, M ^a   Dornhoff, W ^a   Klinkenstein, C ^a   Villena, C ^a   Wilken, H ^a   Cervek, J ^a   Chacon R ^a   Estevez R ^a   Mickiewicz, E ^a   Muro, H ^a   Damianov, D ^a   Donat, D ^a   Vuletic, L ^a   Gershanovich, M N N ^a   Ghilezan, N ^a   Hegg, R ^a   Jassem, J ^a   Pawlicki, M ^a   Ramlau, C ^a   Siedlecki, P ^a   Kocak, I ^a   Korec, S ^a   Muse, I M ^a   Nagykalnai T ^a   Perenyi, L ^a   Pinter, T ^a   Vallejos, C S ^a   Vogel, C ^a   more..

^a NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 0035865148     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.943     Document Type: Article

References (48)

1. Cancer statistics
2. Malignant tumors of the breast
3. Combination chemotherapy as an adjuvant treatment in operable breast cancer
4. Dose response effect of adjuvant chemotherapy in breast cancer
5. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
6. Ten year results of FAC adjuvant chemotherapy trials in breast cancer
7. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
8. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
9. Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors
10. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer
11. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
12. New anthacycline analogs in advanced breast cancer
13. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
14. Phase II study of doxorubicin versus epirubicin in advanced breast cancer
15. Italian multicentre breast study with epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
16. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
17. Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer: Results of a three-arm randomized multicenter trial comparing doxorubicin and mitoxantrone each in combination with cyclophosphamide
18. The importance of dose intensity in chemotherapy of metastatic breast cancer
19. Applications of dose intensity to the problems in chemotherapy of breast cancer and colorectal cancer
20. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
21. High-dose 4′-epiadriamycin for treatment of breast cancer refractory, to standard dose anthracycline chemotherapy: Achievement of second responses
22. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
23. Epirubicin high-dose therapy in advanced breast cancer: Preliminary clinical data
24. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial
25. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
26. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial
27. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: A randomised study in advanced breast cancer
28. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in FEC regimen significantly increases response rates: An international randomized phase III study in metastatic breast cancer
29. A new CMF regimen
30. Reporting results of cancer treatment
31. Introduction to sample size determination and power analysis for clinical trials
32. Nonparametric estimation from incomplete observations
33. Regression models and life tables
34. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer
35. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer
36. Adjuvant anthracycline in breast cancer: Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin
37. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DVATH: A prospective Eastern Cooperative Oncology Group study
38. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
39. Response to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy
40. Salvage chemotherapy for patients suffering relapse after adjuvant CMF chemotherapy
41. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
42. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference
43. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: A phase II study
44. Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive patients
45. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer
46. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
47. Risk factors for doxorubicin-induced congestive heart failure
48. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment